. 2015 Jan 19;100(4):1654–1663. doi: 10.1210/jc.2014-3081

Table 3.

Preintervention to Postintervention Percent Change (%Δ) in mRNA Abundance Measured by qPCR

	Control		Endurance (ET)		Resistance (RT)		Combined (CT)		ANOVA
	Young (n = 12)	Old (n = 10)	Young (n = 11)	Old (n = 11)	Young (n = 11)	Old (n = 9)	Young (n = 12)	Old (n = 9)	Treatment	Age	Treatment × Age
pgc1α	−1 (6)	13 (14)	44 (17)^a,2	15 (16)	80 (62)	36 (9)^b	25 (10)^a	58 (29)	0.28	0.74	0.47
	5 (7)		29 (12)^a		60 (34)		39 (14)^a
pgc1α1	−17 (6)^a	8 (12)	60 (17)^b,2	15 (13)	57 (45)	13 (9)	74 (31)^a,3	74 (37)	0.032	0.38	0.43
	−5 (7)		36 (11)^b,e		38 (25)		74 (23)^b		Control < ET
pgc1α4	−10 (15)	13 (19)	36 (19)	12 (23)	9 (17)	17 (19)	72 (23)^b	102 (61)	0.007	0.61	0.73
	0 (12)		24 (15)		13 (12)		85 (28)^b,d		Control < CT
tfam	−9 (5)	10 (11)	21 (11)	6 (10)	19 (18)	1 (18)	28 (13)	28 (13)	0.21	0.69	0.47
	0 (6)		13 (8)		10 (13)		28 (10)^a		−
nrf1	−6 (2)^a	−1 (10)	−10 (6)	−7 (5)	1 (13)	−17 (6)^a	−4 (5)	9 (8)	0.46	0.87	0.24
	−3 (5)		−8 (4)^a		−7 (16)		1 (5)		−
nrf2	4 (9)	16 (8)	60 (14)^b	15 (14)	30 (27)	22 (15)	12 (7)	16 (11)	0.23	0.39	0.22
	10 (6)		38 (11)^b,d		26 (16)		14 (6)^a		−
sirt1	−1 (3)	−4 (5)	0 (5)	−11 (6)	3 (8)	−12 (6)	2 (5)	7 (4)	0.25	0.15	0.28
	−2 (3)		−6 (4)		−4 (5)		4 (3)		−
sirt3	−5 (2)	−2 (6)	24 (9)^a	11 (9)	11 (10)	11 (5)^a	24 (6)^b	37 (10)^b	0.004	0.89	0.36
	−4 (3)		17 (6)^a,e		11 (6)^d		30 (6)^c,e		Control < ET, RT, and CT
sdhb	1 (7)	0 (8)	46 (11)^b	20 (11)	26 (16)	23 (18)	38 (14)^a	61 (18)^a	0.004	0.89	0.34
	1 (5)		33 (8)^b,e		25 (12)^a		48 (11)^c,e		Control < ET and CT
atpsf1	0 (6)	7 (7)	49 (7)^c	28 (10)^a	28 (19)	25 (16)	28 (8)^b	38 (14)^a	0.02	0.87	0.53
	3 (5)		39 (7)^c,e		26 (13)^a		32 (7)^c,d		Control < ET and CT
cytobc	−3 (4)	0 (5)	24 (9)^a	16 (6)^a	12 (9)	8 (5)	28 (9)^b	23 (7)^a	0.002	0.46	0.89
	−2 (3)		20 (5)^b,e		10 (5)		26 (6)^c,e		Control < ET and CT
cox3	−14 (6)	0 (10)	47 (16)^a	38 (13)^a	50 (39)	38 (18)	65 (18)^b	84 (24)^b	0.002	0.83	0.84
	−8 (6)		42 (70)^c,e		45 (22)^d		73 (14)^c,e		Control < ET, RT, and CT
cox4	−2 (6)	2 (8)	57 (13)^b	30 (13)^a	26 (20)	29 (12)^a	57 (19)^a	66 (21)^a	0.0009	0.78	0.61
	0 (5)		43 (9)^c,e		27 (12)^a,d		61 (14)^{c, e}		Control < ET, RT, and CT
nd4	−10 (6)	11 (16)	41 (12)^b	25 (14)	37 (26)	24 (20)	44 (11)^b	61 (20)^a	0.019	0.86	0.53
	0 (8)		33 (9)^b,e		31 (17)		51 (10)^c,e		Control < ET and CT
myolc	−7 (8)	−7 (11)	15 (9)	161 (139)	14 (9)	54 (53)	51 (25)	96 (54)	0.34	0.16	0.61
	−7 (6)		88 (70)		32 (24)		70 (27)^a
mhcI	−11 (11)	6 (16)	5 (10)	26 (16)	33 (21)	4 (21)	85 (57)	60 (33)	0.06	0.84	0.73
	−3 (9)		15 (10)		20 (15)		74 (35)
mhcIIa	4 (13)	−15 (10)	22 (14)	−6 (15)	51 (33)	3 (16)	13 (11)	40 (19)	0.10	0.87	0.89
	−5 (8)		8 (11)		29 (20)		25 (10)^a
mhcIIx	−9 (14)	0 (15)	−31 (13)^a	−34 (14)^a	−38 (14)^a	−52 (7)^c	−30 (21)	−29 (17)	0.06	0.87	0.89
	−5 (10)		−33 (9)^b		−44 (8)^c		−29 (14)^a

Data are presented as mean (sem). Data in italics are the mean (sem) for the young and old pooled together.

P < .05 (pre vs post);

P < .01 (pre vs post);

P < 0.001 (pre vs post);

P < .05 (treatment vs control);

P < .01 (treatment vs control). ² n = 10; ³ n = 11.